CBLL News & Events

Ceribell sees FY26 revenue $112M-$116M, consensus $113.18M

Reports Q1 revenue $26.5M, consensus $26.09M. "Our strong first quarter performance reflects solid execution against our commercial plan and the clear and growing demand for our seizure monitoring platform," said co-founder and CEO Jane Chao, Ph.D. "The launch of our neonate and pediatric offerings represents a major milestone in our commitment to provide critical brain monitoring for patients of all ages. As we work to redefine the standard of care in seizure management, we will continue to invest in innovation and expansion of our clinical indications to advance our mission to make EEG a new vital sign."

The FDA posted a 510(k) premarket notification notice for the Ceribell Brain Monitor Headband with a decision date of April 3. The FDA decision was "substantially equivalent," according to the post to the agency's site.